NanoViricides (NYSE:NNVC) Stock Price Down 8.2% – Should You Sell?

NanoViricides, Inc. (NYSE:NNVC) shares were down 8.2% during trading on Monday . The company traded as low as $1.10 and last traded at $1.12. Approximately 492,996 shares changed hands during trading, an increase of 100% from the average daily volume of 247,110 shares. The stock had previously closed at $1.22.

NanoViricides Stock Performance

The business has a 50-day moving average of $1.48 and a 200 day moving average of $1.49. The stock has a market cap of $20.16 million, a PE ratio of -1.56 and a beta of 1.15.

Institutional Trading of NanoViricides

A hedge fund recently raised its stake in NanoViricides stock. Susquehanna International Group LLP lifted its holdings in shares of NanoViricides, Inc. (NYSE:NNVC) by 37.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,217 shares of the company’s stock after purchasing an additional 14,217 shares during the quarter. Susquehanna International Group LLP owned about 0.29% of NanoViricides worth $75,000 as of its most recent SEC filing. Institutional investors own 10.30% of the company’s stock.

NanoViricides Company Profile

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.